Chelation Therapy Under Scrutiny

A clinical trial suggesting the heart benefits of the controversial treatment draws criticism from the scientific community.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, WALDSZENENA 10-year, $31.6 million study has found that patients who receive weekly infusions of a chemical that purportedly soaks up metal ions from the blood are less likely to suffer repeat heart attacks. But the trial, which was funded by two National Institutes of Health centers—the National Center for Complementary and Alternative Medicine (NCCAM) and the National Heart, Lung, and Blood Institute (NHLBI)—is being criticized by researchers who are taking issue with the study, its investigators, and its funders. The treatment, called chelation therapy, has long been considered a fringe medical procedure, but is popular in the United States, with more than 110,000 patients undergoing the treatment every year. The new trial found that weekly infusions of a chelating agent called salt of ethylenediaminetetraacetic acid lowered the risk of repeat heart attacks in more than 1,700 patients, though chelation therapy has been linked to heart attacks and death in other studies.

Cleveland Clinic cardiologist Steve Nissen has spoken out about the trial's co-investigators, noting that about 24 of them have been disciplined by state medical boards for insurance fraud and providing ineffective treatments, among other missteps. “They offer aromatherapy, crystal therapy, and every imaginable wacky form of medicine,” Nissen told Nature. “You can’t do high-quality research at sites like that. We wasted $30 million and 10 years on an unreliable study.”

Critics also faulted NCCAM, which often justifies its $128 million annual budget by touting its ability to scientifically debunk unproven and unapproved therapies, for funding the study. “Even if you did pristine research under the NCCAM,” Yale University neurologist Steven Novella told Nature, “it’s what you’re studying that is the problem.”

Nissen offered a dire ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide